相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
进行中（未招募）
1
100.0%
暂无批准数据
- Washington State University researchers used artificial intelligence to find a cheaper, more efficient way to 3D-print the high-performance NASA alloy GRCop-42, avoiding the need to test over 100 million configurations manually. - The AI-guided approach identified six successful printing configurations in three months using just 40 experiments, printing the alloy at 500 watts of laser power for the first time. - The method could expand access to GRCop-42 for universities and smaller labs lacking specialized high-power equipment, while reducing energy use and costs. - The same AI framework holds potential applications beyond manufacturing, including drug discovery and other costly scientific discovery problems.
- A 42-day spaceflight on the ISS led to reduced fertility in female mice, with fewer pups born compared to ground controls. - Offspring of space-flown dams showed altered body weights, behavioral changes, and reduced fecundity over a nine-month period. - Transgenerational effects were observed in grandpups, including altered responses to a high-fat diet, suggesting heritable changes. - Researchers hypothesize mitochondrial dysfunction and epigenetic modifications may underlie the observed reproductive and metabolic changes.
- Redwire's SpaceMD appoints former Merck Principal Investigator Paul Reichert and former NASA Director Niki Werkheiser to strategic advisory roles to advance space-enabled drug development. - Reichert, who contributed to early formulation and crystallization research of pembrolizumab (Keytruda), will identify promising drug candidates and support an orbital research and manufacturing pipeline. - Werkheiser, who oversaw more than $1.5 billion in technology investments at NASA, will develop new therapeutic concepts and expand pharmaceutical research on the ISS and emerging commercial platforms. - The appointments signal growing momentum in the space pharmaceutical sector as SpaceMD accelerates work with a growing number of pharmaceutical customers and partners.
- A study using ISS samples found that spaceflight does not significantly impact cardiac sarcomere function at the myofilament level, suggesting preserved contractile machinery in microgravity. - Proteomic analysis revealed significant immune-related protein changes in heart tissue post-spaceflight, indicating an inflammatory or immune-adaptive response. - The research, published in npj Microgravity, was supported by NIH and NASA grants and provides reassurance about cardiac muscle integrity during long-duration missions. - Findings highlight a divergence between maintained mechanical function and altered molecular signaling, pointing to new avenues for monitoring astronaut cardiovascular health.
- The U.S. Department of Health and Human Services, through ASPR, has launched a prize competition offering up to $2.04 million to strengthen rapid medical supply production and distribution during public health emergencies. - The challenge, facilitated by NASA's CoECI, unfolds in three phases: a conceptual design phase, a development milestone phase, and a final live validation event with real-world simulations. - Up to 8 Phase 1 finalists will receive $5,000 each, with up to 3 winners earning $150,000 each and advancing to development, where additional milestone prizes of up to $150,000 are available. - Phase 1 submissions are due August 28, 2026, with the challenge officially launching on June 15, 2026.
- NASA astronauts successfully 3D-printed high-quality cartilage tissue aboard the International Space Station using a bio-ink containing patient-derived cartilage cells. - The microgravity environment may enable on-demand, personalized medical implants manufactured from a patient's own cells, advancing regenerative medicine. - The experiment is part of broader Expedition 74 biotechnology research including microbial DNA sequencing to identify antibiotic-resistant genes in space. - Insights from space-based bioprinting could lead to breakthroughs in tissue engineering and personalized implant production for patients on Earth.
- The White House Office of Management and Budget (OMB) has proposed a 412-page rule that would fundamentally restructure how federal science agencies award research grants, replacing peer review with political oversight. - Under the proposed changes, senior political appointees would be required to review and approve all grant decisions, with explicit authority to override scientific peer-review panel conclusions. - The rule would ban international scientific collaborations with researchers from certain countries, prohibit research on diversity, equity, and inclusion, and bar grant funds from covering journal publishing fees or conference attendance without prior written approval. - Public comments are open until July 13, 2026, and a large volume of substantive opposition could influence whether the regulations are finalized, changed, or overturned.
- SonoMotion has received FDA 510(k) clearance for its Break Wave device, which uses low-pressure focused ultrasound to fragment kidney stones without requiring anesthesia or dietary restrictions. - The non-invasive system employs standing stress waves guided by real-time ultrasound imaging and can be performed in any healthcare setting with patients fully awake. - Break Wave works alongside Stone Clear, which received FDA de novo clearance in October 2024, to provide a complete anesthesia-free treatment pathway for kidney stone management. - The technology offers immediate treatment options for patients with symptomatic obstructing ureteral stones, potentially eliminating weeks of pain while waiting for stones to pass naturally.
- The FDA approved a new subcutaneous injectable version of pembrolizumab (KEYTRUDA) in September, reducing treatment time from up to two hours to about one minute every three weeks. - Merck's development of this formulation was supported by crystal growth experiments conducted on the International Space Station since 2014, utilizing microgravity conditions to grow higher-quality crystals. - The space-based research provided insights into crystalline suspensions that dissolve easily in liquid, enabling the transition from intravenous infusion to subcutaneous injection delivery. - This advancement promises to reduce costs and significantly improve quality of life for cancer patients while maintaining the drug's efficacy.
- LambdaVision has closed a $7 million seed funding round co-led by Seven Seven Six and Aurelia Foundry to advance clinical development of its protein-based artificial retina for treating retinal degenerative diseases. - The company's innovative artificial retina uses bacteriorhodopsin proteins and is manufactured in microgravity aboard the International Space Station to achieve superior uniformity and optical quality compared to Earth-based production. - The funding, combined with over $18 million in previous NASA and government grants, will support operations through 2027 and advance the technology toward IND-enabling studies for retinitis pigmentosa and age-related macular degeneration patients. - LambdaVision recently received a NASA Phase 2 InSPA award to further develop its space-based manufacturing processes, marking a significant milestone in the commercialization of LEO-based therapeutic production.
